Alex Denner, earlier with Icahn, $2 Billion Man Starts Biotech Hedge Fund

Alex Denner knows how to spot biotechnology companies with promising drugs and make sure investments pay off.

Working as Carl Icahn’s top health-care investing executive for the past five years, Denner has targeted at least six drugmakers from ImClone Systems Inc. to Biogen Idec Inc. (BIIB), prompting sales of three. He’s generated about $2 billion in profit for Icahn, said a person familiar with his record who declined to be identified because the matter is private.

Now the 42-year-old Denner, who has a Ph.D. in biomedical engineering, is splitting with Icahn to start his own hedge fund. As some investors avoid health care, partly because of regulatory hurdles, Denner’s knowledge of science and business gives him an advantage as one of the industry’s few activists

More from here

Bill Gates Changing the World Again, One Vaccine Drop at a Time

How to make GlaxoSmithKline and other pharma giants to produce enough expensive vaccines for children who need them most but can afford them least? The answer, Gates increasingly believed, lay in making Adam Smith’s invisible hand more visible, giving the newly formed market a benevolent shove in the direction of free enterprise.

Thus, in his new avatar (oh well, there are some who say he could make a return to run Microsoft, but that I’m sure, are just rumours), Gates will be changing the world, not one PC at a time, but one vaccine drop at a time.

More from here